INTRODUCTION

“Ceritinib” is the Drug / Molecule content in “Noxalk”. It is an anaplastic lymphoma kinase (ALK) positive inhibitor primarily used for the treatment of metastatic NSCLC. Noxalk thus acts to inhibit mutated enzyme and stop cell proliferation, ultimately halting cancer progression.

Ceritinib works by targeting and blocking receptors found on the cancer cells, which in turn blocks the tumor’s ability to grow. This medication acts specifically on tumors that have an abnormality in a gene called ALK.

Increased alanine transaminase (ALT) Increased aspartate transaminase (AST) Diarrhea Increased gamma-glutamyl transpeptidase (GGT) Increased alkaline phosphatase Increased creatinine Nausea